Adalimumab News and Research RSS Feed - Adalimumab News and Research

Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, announced today that Nature Nanotechnology has published an article that presents preclinical results from Selecta’s research which demonstrate the broad potential applicability of Selecta’s novel immune tolerance platform. [More]
New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016

Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures. [More]
Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that a range of factors other than just cost may influence the prescribing of TNF inhibitors for patients with rheumatoid arthritis (RA). [More]
Antiinflammatory drug HUMIRA enhances specific TNF function in rheumatoid arthritis patients

Antiinflammatory drug HUMIRA enhances specific TNF function in rheumatoid arthritis patients

Researchers from University College London have discovered that the widely used antiinflammatory drug HUMIRA doesn't just work by inhibiting its target protein, TNF, but by enhancing a particular function of TNF in rheumatoid arthritis patients. [More]
New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

About half of Medicare patients who start taking biologic therapies for moderate to severe plaque psoriasis stop within a year, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. [More]
Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24. [More]
AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology. [More]
New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

The new BSR guidelines make a number of specific recommendations for the use of standard and/or biologic disease modifying anti-rheumatic drugs (DMARDs), providing crucial advice for clinicians, obstetricians and midwives. [More]
Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared psoriasis or minimal psoriasis at week 16, the study's primary endpoint. [More]
Guselkumab drug more effective than current standard of care for psoriasis

Guselkumab drug more effective than current standard of care for psoriasis

A phase II clinical trial led by Northwestern Medicine investigators shows that a new psoriasis drug called guselkumab has greater efficacy than the current standard of care for the chronic skin condition. [More]
Study: New test may help predict effectiveness of biologic drugs in RA patients

Study: New test may help predict effectiveness of biologic drugs in RA patients

A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them. [More]
3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006. [More]
Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study shows that TNFi dose reduction strategy can help in optimal management of RA

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third. [More]

Study indicates that arthritis patients may not be taking medication as regularly as prescribed

Researchers from the Arthritis Research UK Centre for Epidemiology at The University of Manchester found that 40% of patients scored low on an adherence questionnaire at least once during their time in a recent study, indicating that they might not be taking their expensive biological therapies as regularly as prescribed. [More]
Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets. [More]
Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints. [More]
NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies. [More]
Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy. [More]
Australian Prescriber publishes top 10 subsidised drugs in Australia

Australian Prescriber publishes top 10 subsidised drugs in Australia

The annual publication of the top 10 subsidised drugs appears in the December edition of Australian Prescriber. Statins (cholesterol-lowering medicines) top the lists again. [More]
AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. [More]
Advertisement
Advertisement